139 related articles for article (PubMed ID: 23763380)
21. Antinuclear antibodies (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance.
Yee LJ; Kelleher P; Goldin RD; Marshall S; Thomas HC; Alberti A; Chiaramonte M; Braconier JH; Hall AJ; Thursz MR
J Viral Hepat; 2004 Sep; 11(5):459-64. PubMed ID: 15357653
[TBL] [Abstract][Full Text] [Related]
22. Antineutrophil cytoplasmic antibody in patients with antinuclear antibody-positive chronic hepatitis C.
Ohira H; Tojo J; Shinzawa J; Suzuki T; Miyata M; Nishimaki T; Kasukawa R
Fukushima J Med Sci; 1998 Dec; 44(2):83-92. PubMed ID: 10091380
[TBL] [Abstract][Full Text] [Related]
23. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
[TBL] [Abstract][Full Text] [Related]
24. Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant.
Kamar N; Ribes D; Izopet J; Rostaing L
Transplantation; 2006 Oct; 82(7):853-6. PubMed ID: 17038897
[TBL] [Abstract][Full Text] [Related]
25. Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4.
Saad Y; Ahmed A; Saleh DA; Doss W
Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):920-5. PubMed ID: 23442415
[TBL] [Abstract][Full Text] [Related]
26. Investigation and analysis of HEp 2 indirect immunofluorescence titers and patterns in various liver diseases.
Wei Q; Jiang Y; Xie J; Yang M; Zhang Y; Wu Z; Chen S; Liao Z; Lin Z; Gu J
Clin Rheumatol; 2020 Aug; 39(8):2425-2432. PubMed ID: 32103375
[TBL] [Abstract][Full Text] [Related]
27. Expression and clinical significance of antinuclear antibody in hepatitis C virus infection.
Peng YC; Hsieh SC; Yang DY; Tung CF; Hu WH; Huang WN; Chen GH
J Clin Gastroenterol; 2001; 33(5):402-6. PubMed ID: 11606858
[TBL] [Abstract][Full Text] [Related]
28. Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: a pilot study.
Gatselis NK; Georgiadou SP; Tassopoulos N; Zachou K; Liaskos C; Hatzakis A; Dalekos GN
World J Gastroenterol; 2005 Jan; 11(4):482-7. PubMed ID: 15641130
[TBL] [Abstract][Full Text] [Related]
29. Clinical correlates of the "rods and rings" antinuclear antibody pattern.
Climent J; Morandeira F; Castellote J; Xiol J; Niubó J; Calatayud L; Mestre M; Bas J
Autoimmunity; 2016; 49(2):102-8. PubMed ID: 26699543
[TBL] [Abstract][Full Text] [Related]
30. Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma.
Imai H; Nakano Y; Kiyosawa K; Tan EM
Cancer; 1993 Jan; 71(1):26-35. PubMed ID: 8380118
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of the antinuclear antibodies in chronic viral hepatitis B in children.
Pop TL; Stefănescu A; Samaşca G; Miu N
Clin Lab; 2014; 60(6):931-9. PubMed ID: 25016697
[TBL] [Abstract][Full Text] [Related]
32. Autoimmunity and lymphoproliferation markers in naïve HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders.
Gulli F; Basile U; Gragnani L; Fognani E; Napodano C; Colacicco L; Miele L; De Matthaeis N; Cattani P; Zignego AL; Rapaccini GL
Dig Liver Dis; 2016 Aug; 48(8):927-33. PubMed ID: 27289333
[TBL] [Abstract][Full Text] [Related]
33. High prevalence of antinuclear antibodies in patients with chronic hepatitis C virus infection.
de Castro GLC; da Silva Graça Amoras E; Araújo MS; da Silva Conde SRS; Bichara CDA; Queiroz MAF; Vallinoto ACR
Eur J Med Res; 2022 Sep; 27(1):180. PubMed ID: 36114565
[TBL] [Abstract][Full Text] [Related]
34. Correlation of autoimmune reactivity with hepatitis B and C virus (HBV and HCV) infection in histologically proven chronic liver diseases.
Shantha S; Thyagarajan SP; Premavathy RK; Sukumar RG; Mohan KV; Palanisamy KR; Rajasambandam P
Indian J Med Microbiol; 2002; 20(1):12-5. PubMed ID: 17657016
[TBL] [Abstract][Full Text] [Related]
35. Assessment of the Prevalence of Non-Organ-Specific Autoantibodies in Egyptian Patients with HCV.
Emara M; Mohsen E; Shawky RM; El-Domany RA
Immunol Invest; 2020 Aug; 49(6):676-686. PubMed ID: 31820668
[TBL] [Abstract][Full Text] [Related]
36. Induction of antinuclear antibody after interferon therapy in patients with type-C chronic hepatitis: its relation to the efficacy of therapy.
Noda K; Enomoto N; Arai K; Masuda E; Yamada Y; Suzuki K; Tanaka M; Yoshihara H
Scand J Gastroenterol; 1996 Jul; 31(7):716-22. PubMed ID: 8819224
[TBL] [Abstract][Full Text] [Related]
37. Autoantibody prevalence in children with liver disease due to chronic hepatitis C virus (HCV) infection.
Gregorio GV; Pensati P; Iorio R; Vegnente A; Mieli-Vergani G; Vergani D
Clin Exp Immunol; 1998 Jun; 112(3):471-6. PubMed ID: 9649217
[TBL] [Abstract][Full Text] [Related]
38. [The detection of anti-nuclear antibody and IL-21 in patients infected with hepatitis C virus].
Zou M; Li MM; Huang SB; Li XJ; Zhou YP; Liu SW
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 May; 26(5):471-2. PubMed ID: 20423656
[TBL] [Abstract][Full Text] [Related]
39. Diversity of antinuclear antibody responses in hepatocellular carcinoma.
Covini G; von Mühlen CA; Pacchetti S; Colombo M; Chan EK; Tan EM
J Hepatol; 1997 Jun; 26(6):1255-65. PubMed ID: 9210612
[TBL] [Abstract][Full Text] [Related]
40. Temporal evolution of human autoantibody response to cytoplasmic rods and rings structure during anti-HCV therapy with ribavirin and interferon-α.
Keppeke GD; Satoh M; Ferraz ML; Chan EK; Andrade LE
Immunol Res; 2014 Oct; 60(1):38-49. PubMed ID: 24845459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
